Risk of bias
| Study (author and year) | Adequate sequence generation | Allocation concealment | Masking | Incomplete outcome data addressed | Free of selective reporting | Free of other bias (eg, similarity at baseline, power assessment) | Funder |
|---|---|---|---|---|---|---|---|
| Geneva 20106–8 | Low | Low | Partial: patients and assessors of efficacy variables | Low: ITT analysis, 94% FU at 6 months | Low | Power: 81% power to detect difference in primary outcome with n=495 for each trial Similarity at baseline: yes | Allergan Inc |
| Score 200923–36 | Low | Unclear | Partial (physicians and patients masked to dose but not triamcinolone vs observation) | Low: ITT analysis, 83–90% FU at 12 months | Low | Power: 80% power to detect difference in primary outcome with n=486 (but only 271 randomised) Similarity at baseline: yes | National Eye Institute grants, Allergan |
| Copernicus 201212 13 | Low | Unclear | Low: double-blind | Low: ITT analysis, 89.9% assessed at primary end point | Low | Power: 90% power to detect difference in primary outcome with n=165 Similarity at baseline: yes | Bayer HealthCare, Regeneron Pharmaceuticals |
| Galileo 201211 | Unclear | Unclear | Low: double-blind | Low: ITT analysis, 86% assessed at primary end point | Low | Power: 90% power to detect difference in primary outcome with n=150 Similarity at baseline: yes | Bayer HealthCare, Regeneron Pharmaceuticals |
| Cruise 20109 10 | Low | Unclear | Low: patients and evaluating examiners, injecting physicians masked to dose | Low: ITT analysis, 88.5–97.7% completed 6 months | Low | Power: not reported Similarity at baseline: yes | Genentech Inc. |
| Epstein 201242–44 | Unclear | Low | Low: patients, outcome assessors | Low: ITT analysis; missing data for 2 patients (primary endpoint) | Low | Power: 80% power to detect difference in primary outcome with n=24 per group Similarity at baseline: yes | Unclear; authors are consultants for Allergan, Novartis, Alcon, Bayer |
FU, follow-; ITT, intention to treat.